Zymeworks

Rank#5032

Market Cap2.01B

CountryCanada

Summary

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

History

Zymeworks was founded in 2003 by Dr. Ali Tehrani and Dr. Jayarama Akkiraju. We have a proven track record in drug discovery, research, development, and clinical validation as recognized through multiple regulatory and partnering milestones. Zymeworks enables the development of novel therapeutics that are designed for improved pharmacological activity, immunogenicity and safety, multi-efficacy and manufacturability.

Mission

Zymeworks’ mission is to develop transformative therapies that benefit patients.

Vision

Zymeworks’ vision is to leverage our proprietary technology platforms and innovative drug discovery and development capabilities to become a leader in the development of transformative biotherapeutics.

References

https://en.wikipedia.org/wiki/Zymeworks

https://in.investing.com/equities/zymeworks-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/zymeworks

https://finance.yahoo.com/quote/ZYME/

https://www.zymeworks.com

https://sec.report/CIK/0001937653

Leadership team

Mr. Neil A. Klompas C.A., CPA, CA, CPA (Pres & COO)

Dr. Ali Tehrani Ph.D. (Advisor)

Dr. Neil Josephson M.D. (Chief Medical Officer)